Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and ...

EXTON, PA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Since the first US FDA-approved tumor necrosis factor (TNF) inhibitor in 2002 for the treatment of psoriatic arthritis (PsA), TNF’s have upheld

Related Keywords

Germany ,Maxine Yarnall ,Eli Lilly Taltz ,Novartis Cosentyx ,Linkedin ,Spherix Network ,Twitter ,Eli Lilly ,Spherix Global Insight Realtime Dynamix ,Psoriatic Arthritis ,Realtime Dynamix ,Time Dynamix ,Global Insights ,Spherix Global Insights ,Spherix Global Insight ,Region ,